Pacific Biosciences of California Overview
Valuation check: PACB's ROE is 395.59%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow395.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Pacific Biosciences of California (PACB) currently reports a ROE of 395.59%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Pacific Biosciences of California's ROE history and peer comparisons.
Pacific Biosciences of California's ROE of 395.59% is higher than the Healthcare sector average of 22.01%. That is roughly 1697.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Pacific Biosciences of California's current 395.59% should be judged against Healthcare norms (sector average: 22.01%) and against PACB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 395.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Pacific Biosciences of California, and consider following PACB for alerts when major investors trade the stock.
Pacific Biosciences of California is classified in the Healthcare sector. On ROE, it currently shows 395.59% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PACB with unrelated industries.
